Exact Sciences (EXAS) Tops Q3 EPS by 23c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Exact Sciences Announces Third Quarter 2022 Results
November 3, 2022 4:05 PM EDTReports Record Revenue, Raises Full-Year Guidance, Accelerates Path to Profitability
Third quarter highlights
Total third quarter revenue, excluding COVID-19 testing, increased 20 percent compared to the third quarter of 2021, with Screening revenue of $361 million and Precision Oncology revenue of $151 millionFull-year revenue guidance raised by $33 million and operating expense guidance lowered by $113 million at the midpointsAdjusted EBITDA profitability now expected in the third quarter of 2023, ahead of previous target of 2024MADISON, Wis., Nov. 3, 2022 /PRNewswire/... More
